关键词 呋喹替尼 莱姆病疫苗 CAR-T 二甲双胍 肿瘤 KIR 淀粉样蛋白β 阿尔茨海默病 重组蛋白 奈莫利珠单抗 #今日行业热点#①The Lancet：Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study 临床研究：呋喹替尼与安慰剂在难治性转移性结直肠癌患者中的比较(FRESCO-2):一项国际性、多中心、随机、双盲、Ⅲ期研究 DOI: 10.1016/S0140-6736(23)00772-9 ②The Lancet Infectious Diseases：Safety and immunogenicity of a novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a randomised, phase 1 study in healthy adults 临床试验：新型多价莱姆病候选疫苗的安全性和免疫原性:一项在健康成人中进行的随机、Ⅰ期研究 DOI: 10.1016/S1473-3099(23)00210-4 ③The Lancet Oncology：Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study 临床研究：使用人源化的靶向BCMA的CAR-T细胞疗法ARI0002h用于复发或难治性多发性骨髓瘤(CARTBCMA-HCB-01)患者:一项单臂、多中心的学术试点研究 DOI: 10.1016/S1470-2045(23)00222-X ④The Lancet Diabetes and Endocrinology：Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial 临床试验：二甲双胍联合生活方式干预与单独生活方式干预在中国糖调节受损参与者中预防糖尿病的安全性和有效性比较:一项多中心、开放标签、随机对照试验 DOI: 10.1016/S2213-8587(23)00132-8 ⑤EBioMedicine：Evaluation of four tumour growth models to describe the natural history of meningiomas 评估四种肿瘤生长模型以描述脑膜瘤的自然病程并分析肿瘤生长和快速生长的预测因素 DOI: 10.1016/j.ebiom.2023.104697 ⑥EBioMedicine：Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study 临床研究：抗淀粉样蛋白β的活性免疫治疗性疫苗UB-311在轻度阿尔茨海默病参与者中的安全性、耐受性、免疫原性和有效性:一项随机、双盲、安慰剂对照的2a期研究 DOI: 10.1016/j.ebiom.2023.104665 ⑦重组ADAMTS13蛋白TAK-755用于降低先天性血栓性血小板减少性紫癜（cTTP）风险的国际Ⅲ期临床中期结果积极 ⑧靶向IL-31受体α的全球首创单克隆抗体奈莫利珠单抗（Nemolizumab）用于成人结节性痒疹的Ⅲ期研究最新数据公布 ⑨高选择性JAK抑制剂乌帕替尼第5个适应症在华获批，用于对一种或多种肿瘤环死因子（TNF）抑制剂应答不佳或不耐受或禁忌的中度至重度活动性克罗恩病 ⑩新一代EGFR Exon20ins抑制剂ABSK112获美国食品药品管理局(FDA)临床试验批准，将开展针对非小细胞肺癌 (NSCLC)的国际首次人体I期临床试验 科学探索的世界充满挑战，AtaGenix致敬每一位拓荒者，更致力于成为您信赖的合作伙伴！ |
|
|
